Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
A thorough discussion with a healthcare provider can offer personalized insights and reassurance
Dysesthesia signal (Phase 3) TRIUMPH-4 topline results, released December 11, 2025, reported dysesthesia in about 20.9% of participants at the highest dose
I feel like my confidence has come back and Ive started to rediscover myself
Individuals with a history of recurrent UTIs, women, the elderly, and those with compromised immune systems may be at higher risk and should take additional precautions
While it can happen with the injectable form too, it's much less common (2% compared to placebo)
It is approved for chronic weight management in adults and children 6 years and older with obesity due to specific genetic conditions, including proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome
